每经AI快讯，7月30日，深交所公告，港股通标的证券名单发生调整并自2025年07月30日起生效，调出 东阳光（600673）长江药业。 ...

智通财经7月30日电，深交所公告，港股通标的证券名单发生调整并自2025年07月30日起生效，调出东 阳光长江药业。 ...

Group 1 - Dongyangguang Pharmaceutical has completed its last trading day and is set to launch on the Hong Kong Stock Exchange, marking the first instance of "H-share absorption merger privatization + introduction listing" in the market [1] - The company plans to list as "Dongyangguang Pharmaceutical" (stock code: 06887.HK) on August 7, 2023, creating a new paradigm for asset securitization among Chinese innovative pharmaceutical companies [1] - This listing does not involve new share issuance or fundraising; instead, it involves the absorption merger of its Hong Kong-listed subsidiary, Dongyangguang Changjiang Pharmaceutical, allowing small shareholders to exchange their shares for H-shares [1] Group 2 - Industry insiders note that this approach breaks traditional capital operation time barriers, reduces funding friction costs associated with acquisitions, and effectively safeguards shareholder rights [1] - The move is seen as a model for resource integration and capital upgrade, providing a reference for industrial consolidation and international development, aligning with national strategies to optimize capital market structures [1] - After the Hong Kong listing, Dongyangguang Pharmaceutical is expected to gain long-term capital support and achieve integrated industry upgrades, combining its R&D capabilities with the nationwide sales network of Dongyangguang Changjiang Pharmaceutical [1][2]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600682 | 南京新白 | 7.43 | -2.24% | 77.48万 | 5.74亿 | | 000632 | 三木集团 | 4.06 | -2.17% | 17.94万 | 7290.78万 | | 002758 | 浙农股份 | 9.22 | -1.50% | 6.39万 | 5878.08万 | | 600881 | 亚泰集团 | 1.83 | -1.08% | 60.58万 | 1.11亿 | | 000421 | 南京公用 | 6.83 | -1.01% | 9.45万 | 6416.93万 | | 600051 | 宁波联合 | 7.66 | -0.91% | 5.58万 | 4261.73万 | | 000753 | 漳州发展 | 5.64 | -0.88% | 28.67万 | 1.61亿 | | 600620 | 天宸股份 | 6.34 | -0.78% | 12.94万 | 8185.07万 | | 600770 | 综 ...

| 证券代码：600673 | 证券简称：东阳光 | | 编号：临 2025-48 号 | | --- | --- | --- | --- | | 债券代码：242444 | 债券简称：25 东科 | 01 | | 广东东阳光科技控股股份有限公司 关于控股股东及其一致行动人部分股份解质押的公告 截至本公告披露日，公司控股股东累计质押股数数量为 551,798,054 股， 占其持股数量的 89.34%；控股股东及其一致行动人累计质押股数数量为 1,244,388,597 股，占合计持股数量比例为 78.36%。 一、本次股份解质押基本情况 广东东阳光科技控股股份有限公司（以下简称"公司"）于近日收到控股股 东深圳东阳光实业及其一致行动人宜昌药业股份的通知，获悉其将其持有的公司 部分无限售流通股进行了解质押，具体事项如下： | 股东名称 | 深圳市东阳光实业发展有限公司 | 宜昌东阳光药业股份有限公司 | | --- | --- | --- | | 本次解质押股数 | 10,000,000 股 | 10,000,000 股 | | 占其所持股份比例 | 1.62% | 1.83% | | 占公司总股本比例 | ...

Investment Rating - The report maintains a positive outlook on the pesticide industry, suggesting a "Buy" rating for key companies such as Yangnong Chemical, Lier Chemical, and Runfeng Shares [3][20]. Core Insights - The pesticide industry is experiencing a recovery due to the "Zhengfeng Zhijuan" initiative aimed at regulating the market, which has led to price increases for key products like fluorocarbon herbicides [3][4]. - The report highlights the impact of maintenance shutdowns at major production facilities, such as Wanhua's Hungarian plant, which may lead to supply shortages and price increases in the TDI market [3][4]. - The report emphasizes the potential for improved industry dynamics through the elimination of outdated production capacity, as indicated by government initiatives targeting key sectors [3][4]. Summary by Sections Industry Dynamics - Current macroeconomic conditions indicate a stable global GDP growth of 2.8%, with oil demand expected to rise despite some slowdown due to tariffs [4]. - The report notes that coal prices are expected to decline in the medium to long term, alleviating pressure on downstream industries [4]. Chemical Prices - Recent price movements include a 15% increase in the price of Lier Chemical's fluorocarbon herbicide and a similar rise for Zhongqi Shares [3][11]. - The report mentions that the price of TDI is expected to rise due to low global inventory levels and potential supply disruptions from maintenance activities [3][4]. Investment Recommendations - The report suggests focusing on traditional cyclical stocks and specific sectors such as coal chemical, real estate chain, and agricultural chemicals, highlighting companies like Wanhua Chemical and Hualu Hengsheng [3][20]. - Growth stocks with recovery potential are identified, including semiconductor materials and OLED panel materials, with specific companies recommended for investment [3][20].

Core Viewpoint - Dongyangguang Pharmaceutical is on the verge of officially listing on the Hong Kong Stock Exchange after successfully passing the necessary shareholder votes for privatization and merger with its subsidiary Dongyangguang Changjiang Pharmaceutical [1][2]. Group 1: Listing Process - Dongyangguang Pharmaceutical announced its application for listing on June 29, and the final step involves the approval of the privatization and merger proposal, which received over 99% support from shareholders on July 21 [1][2]. - The company will commence trading on the Hong Kong Stock Exchange on August 7, 2023 [2]. Group 2: Merger and Share Exchange - The listing will occur through a unique method of "absorption merger + introduction," marking a first in the Hong Kong market [3]. - The share exchange ratio is set at 0.263614 shares of Dongyangguang Pharmaceutical for each share of Dongyangguang Changjiang Pharmaceutical, with the theoretical value of Dongyangguang Pharmaceutical's H-shares estimated between 67.04 HKD and 81.44 HKD by the end of 2024 [4]. Group 3: Special Dividend and Shareholder Benefits - Shareholders of Dongyangguang Changjiang Pharmaceutical will receive a special dividend of 1.50 HKD per share post-merger, with approximately 4.28 billion H-shares eligible for this dividend [4][6]. - The potential premium for minority shareholders, considering the privatization and special dividend, could exceed 40% since the stock price on June 27 was 14.90 HKD, while the estimated value during privatization is around 19.36 HKD [4][6]. Group 4: Growth Potential and Innovation - Dongyangguang Pharmaceutical has seen a stock price increase of over 70% year-to-date, indicating strong market performance [6]. - The company has developed a comprehensive R&D platform over 20 years, with 150 drugs available globally and over 100 in development, including 49 first-class innovative drugs with significant commercial potential [6][7]. - Notable drugs include Clifofitinib, with a peak sales potential of 1 billion USD, and another drug, Ifenidone, which shows promise in treating various conditions [7].

Group 1 - UBTECH announced its fifth equity financing since its IPO, aiming to raise approximately HKD 24.73 billion by issuing about 30.16 million new H-shares at HKD 82.00 per share, which is a discount of about 9.14% from the closing price on July 21, 2025 [1] - The total amount raised by UBTECH, including the IPO, has reached HKD 55.82 billion, corresponding to approximately 13.85% of the company's total share capital post-financing [1] Group 2 - GoerTek submitted a prospectus to the Hong Kong Stock Exchange for its subsidiary, GoerTek Microelectronics, aiming for a listing on the main board, marking its second attempt after a previous application lapsed on January 20, 2025 [2] - GoerTek Microelectronics holds a 4.3% market share in the global sensor market, ranking fourth, and a 43.0% share in the acoustic sensor market, ranking first [2] Group 3 - Xiechuang Data announced plans for an IPO in Hong Kong to enhance its international strategy and overseas financing capabilities, focusing on IoT smart terminals and data storage devices [3] - The company, which was listed on the Shenzhen Stock Exchange in July 2020, currently has a market capitalization of approximately RMB 27.51 billion [3] Group 4 - Dongyang Sunshine Pharmaceutical's absorption merger plan was approved with over 99% support at a shareholder meeting, marking a significant step in its listing process, with plans to officially list on August 7 [4] - This merger represents the first case of an H-share absorption merger and privatization listing on the Hong Kong Stock Exchange, avoiding new share issuance while achieving asset integration [4] Group 5 - The Hang Seng Index closed at 25,130.03, with a gain of 0.54% on July 22 [5] - The Hang Seng Tech Index and the National Enterprises Index also saw increases of 0.38% and 0.39%, closing at 5,606.83 and 9,075.60 respectively [5]

今年以来，氟化工板块价格指数震荡上行。据东方财富网统计，7月18日氟化工板块价格指数为 3561.25，比2024年年底上涨了16.65%。巨化股份、三美股份、永和股份、东阳光等行业龙头企业半年 度业绩预告均显示，归母净利润同比增长超过100%。值得注意的是，上述企业的预增公告均表示，业 绩增长的核心驱动力来自氟制冷剂的价格攀升。 永和股份预计上半年归母净利润同比增长126.30%~148.49%。永和股份表示，他们依托配额优势，积极 把握制冷剂产品市场价格上行机遇，实现制冷剂业务盈利能力显著提升。 东阳光在半年度业绩预告中表示，预计实现归母净利润同比增长157.48%~192.81%。该公司表示，随着 全球第三代制冷剂市场需求不断提升，行业供需结构得到深度改善，制冷剂价格持续攀升，为经营利润 的提升提供了支撑。 双轮驱动市场上行 业内人士也表示，制冷剂市场此轮上涨的原因是政策加供需双轮驱动所致。 龙头企业业绩领跑 多家氟化工企业亮出了2025年上半年"成绩单"。 巨化股份作为国产氟化制冷剂的绝对领导者，以37.86%的第三代制冷剂配额份额稳居全国第一。在制 冷剂价格同比上涨62%的推动下，巨化股份2025年 ...

Group 1 - Chipan Intelligent has completed a seed round financing of several tens of millions of RMB, with Dongyangguang as the exclusive strategic investor and Guangyuan Capital participating in incubation and serving as the exclusive financial advisor [1] - The funds from this round of financing will primarily be used for the research and development of gas-liquid phase change liquid cooling technology, with prototype production, production line construction, and small batch delivery expected by 2025 [1] - This strategic financing will expand the business cooperation between Chipan Intelligent and upstream industry chain partner Dongyangguang Group in fields such as fluorine chemicals, promoting the application of phase change liquid cooling technology in high-performance data centers [1][3] Group 2 - Chipan Intelligent, established in 2025, possesses core technology in adaptive dual-phase liquid cooling intelligent control and has developed technologies for dual-phase flow perception and intelligent control [3] - The company has overcome industry bottlenecks in high-density heat dissipation efficiency, energy efficiency optimization, and material compatibility, positioning itself as a potential leader in the liquid cooling sector [3][4] - Dongyangguang's investment manager Liu Qiong highlighted Chipan Intelligent's leading technological innovation and engineering capabilities in the dual-phase immersion liquid cooling field, with products validated by several leading enterprises [3][4] Group 3 - Guangyuan Capital's incubation head Huang Xinxin noted that Chipan Intelligent has achieved a critical breakthrough from core technology to industrialization in the domestic high-end liquid cooling sector, becoming an important driver for industry technological upgrades and green transformation [4] - Dongyangguang plans to engage in strategic cooperation with Chipan Intelligent in areas such as fluorine chemical materials and liquid cooling integrated machine sales, continuously empowering its industrialization process [4]